Revolution’s lead RAS blocker heads into Phase 3 in frontline pancreatic cancer after early data

Revolution Medicines said it will begin a late-stage test of its lead asset as a first-line treatment for a form of pancreatic cancer, after a Phase 1 study in this setting yielded promising data. ...